Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
62°
Sunny
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ardelyx, Inc.
< Previous
1
2
Next >
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
May 16, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
May 14, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
May 07, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
May 02, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
May 01, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
April 18, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
March 28, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
March 25, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
March 12, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
February 27, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 22, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
February 01, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
January 12, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
January 08, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
January 03, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
December 20, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
November 21, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
November 15, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces Departure of Board Member
November 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Participate at the Jefferies London Healthcare Conference
November 10, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
November 06, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
November 03, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
October 31, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
October 30, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
October 23, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
October 18, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
October 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
October 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
October 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.